Cepheid (NASDAQ:CPHD)’s share price traded up 5.5% during mid-day trading on Friday . The company traded as high as $33.32 and last traded at $33.10, with a volume of 290,458 shares. The stock had previously closed at $31.37.

Several brokerages have issued reports on CPHD. Needham & Company LLC reissued a “buy” rating on shares of Cepheid in a report on Saturday, April 30th. Canaccord Genuity reissued a “hold” rating on shares of Cepheid in a report on Saturday, April 30th. Zacks Investment Research lowered shares of Cepheid from a “buy” rating to a “hold” rating in a report on Wednesday, May 4th. Morgan Stanley began coverage on shares of Cepheid in a report on Wednesday, June 15th. They issued an “equal weight” rating and a $30.00 price target on the stock. Finally, TheStreet raised shares of Cepheid from a “sell” rating to a “hold” rating in a report on Tuesday, April 26th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and thirteen have assigned a buy rating to the company. Cepheid presently has a consensus rating of “Hold” and a consensus price target of $41.58.

The firm’s 50 day moving average price is $29.21 and its 200 day moving average price is $31.14. The stock’s market cap is $2.43 billion.

Cepheid (NASDAQ:CPHD) last issued its quarterly earnings results on Thursday, April 28th. The company reported $0.08 EPS for the quarter, topping the Zacks’ consensus estimate of $0.01 by $0.07. The company earned $144.80 million during the quarter, compared to the consensus estimate of $140.35 million. The firm’s revenue for the quarter was up 9.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.17 EPS. Analysts predict that Cepheid will post $0.25 earnings per share for the current fiscal year.

In other Cepheid news, CEO John L. Bishop sold 110,000 shares of Cepheid stock in a transaction dated Monday, April 25th. The stock was sold at an average price of $35.50, for a total value of $3,905,000.00. Following the transaction, the chief executive officer now owns 194,449 shares in the company, valued at $6,902,939.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Scott A. Campbell sold 2,058 shares of Cepheid stock in a transaction dated Tuesday, May 3rd. The shares were sold at an average price of $27.90, for a total value of $57,418.20. Following the completion of the transaction, the vice president now owns 13,761 shares in the company, valued at approximately $383,931.90. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors have added to or reduced their stakes in the stock. Stephens Investment Management Group LLC boosted its position in Cepheid by 17.0% in the fourth quarter. Stephens Investment Management Group LLC now owns 964,912 shares of the company’s stock worth $35,248,000 after buying an additional 140,090 shares in the last quarter. American Capital Management Inc. boosted its position in Cepheid by 48.2% in the fourth quarter. American Capital Management Inc. now owns 529,840 shares of the company’s stock worth $19,355,000 after buying an additional 172,225 shares in the last quarter. Gamco Investors INC. ET AL boosted its position in Cepheid by 7.9% in the fourth quarter. Gamco Investors INC. ET AL now owns 231,500 shares of the company’s stock worth $8,457,000 after buying an additional 17,000 shares in the last quarter. Columbia Wanger Asset Management LLC boosted its position in Cepheid by 5.2% in the fourth quarter. Columbia Wanger Asset Management LLC now owns 5,360,677 shares of the company’s stock worth $195,826,000 after buying an additional 265,403 shares in the last quarter. Finally, Rhumbline Advisers boosted its position in Cepheid by 5.5% in the fourth quarter. Rhumbline Advisers now owns 86,191 shares of the company’s stock worth $3,149,000 after buying an additional 4,495 shares in the last quarter.

Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company’s systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.